High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation

NCT02404675 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC

Interventions

DRUG: icotinib

Sponsor

Betta Pharmaceuticals Co., Ltd.